云南白药(000538) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 10,327,715,582.47, representing a 33.38% increase compared to CNY 7,743,346,885.10 in the same period last year[3]. - Net profit attributable to shareholders was CNY 763,157,801.48, a decrease of 40.48% from CNY 1,282,090,210.08 year-on-year[3]. - The net profit excluding non-recurring gains and losses was CNY 1,365,307,573.86, which is a 29.42% increase from CNY 1,054,950,137.98 in the previous year[3]. - Basic earnings per share decreased by 40.40% to CNY 0.60 from CNY 1.00 in the previous year[3]. - Operating profit decreased to CNY 881,246,060.30, down 41.8% from CNY 1,513,329,925.09 year-over-year[41]. - Net profit for the quarter was CNY 761,866,576.33, a decline of 40.5% compared to CNY 1,283,367,248.91 in the previous year[41]. - The company recorded a total comprehensive income of CNY 952,659,319.83, compared to CNY 1,274,972,049.96 in the same quarter last year[41]. Cash Flow - The net cash flow from operating activities was negative CNY 128,050,971.43, a decline of 125.96% compared to CNY 493,230,793.57 in the same period last year[3]. - The cash inflow from operating activities for the current period is CNY 8,649,635,096.06, an increase of 2.65% compared to CNY 8,426,640,166.38 in the previous period[44]. - The cash outflow from operating activities for the current period is CNY 8,777,686,067.49, up 10.67% from CNY 7,933,409,372.81 in the previous period[45]. - The cash inflow from investment activities is CNY 1,009,365,742.22, significantly higher than CNY 114,901,051.59 in the previous period[45]. - The net cash flow from investment activities is CNY 603,737,239.24, a recovery from a negative CNY 824,271,640.86 in the previous period[45]. - The cash outflow from financing activities is CNY 1,059,091,292.61, compared to CNY 7,805,529.63 in the previous period[46]. - The net cash flow from financing activities is CNY -1,029,091,292.61, a decline from CNY 1,144,667,164.09 in the previous period[46]. - The company reported a net decrease in cash and cash equivalents of CNY -553,434,963.73, compared to an increase of CNY 813,626,316.80 in the previous period[46]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 53,797,491,344.84, down 2.58% from CNY 55,219,448,243.00 at the end of the previous year[3]. - The total liabilities decreased to CNY 14,500,781,715.52 from CNY 16,875,427,831.52, indicating a reduction of about 14.1%[35]. - The total assets amounted to CNY 40,706,617,404.55, down from CNY 41,449,216,095.58, reflecting a decrease of approximately 1.8%[37]. - The company's cash and cash equivalents stood at CNY 14.93 billion, down from CNY 15.28 billion[32]. - The total current assets decreased to CNY 47.90 billion from CNY 49.26 billion[32]. - The company's retained earnings increased to CNY 19,604,386,618.87 from CNY 18,841,228,817.39, reflecting a growth of approximately 4.1%[35]. Investments - The company reported a total investment in Xiaomi Group shares of CNY 1,631,800,843.40, with a fair value loss of CNY 692,579,642.46 during the reporting period[23]. - The company holds shares in Yili Group with an initial investment of CNY 887,169,907.97, resulting in a fair value loss of CNY 110,750,910.62[23]. - The company has invested CNY 841,277,477.20 in fixed-income funds, with a fair value gain of CNY 9,092,888.30 during the reporting period[23]. - The company reported a fair value loss of CNY 10,594,607.89 on its investment in Bosera Macro Fund, with an initial investment of CNY 615,532,418.56[23]. Shareholder and Equity Information - The net assets attributable to shareholders increased by 2.51% to CNY 39,006,530,456.04 from CNY 38,052,550,013.05 at the end of the previous year[3]. - The top shareholder, Yunnan State-owned Assets Management Co., Ltd., holds 25.14% of the shares, while Xinhua Dou Industrial Group Co., Ltd. holds 24.37%[6]. - The company plans to distribute a cash dividend of 39 RMB per 10 shares, totaling approximately 4.92 billion RMB, based on a total share capital of 1,260,703,320 shares after accounting for repurchased shares[17]. - The employee stock ownership plan will involve a maximum of 16,699,997 shares, representing 1.31% of the company's total share capital, with a purchase price set at 70.19 RMB per share[18]. - The company has proposed to authorize the board to handle matters related to the 2021 employee stock ownership plan[22]. Operational Changes and Future Plans - The company has established a new organizational structure comprising four platforms: industrial platform, functional support platform, shared service platform, and innovation incubation platform[19]. - The company plans to transfer its equity in Yunnan Yun Pharmaceutical Co., Ltd. to its wholly-owned subsidiary Yunnan Baiyao Group (Hainan) Co., Ltd. at a book value of approximately ¥417.64 million[15]. - The company intends to establish a wholly-owned subsidiary in Hong Kong with an investment of HKD 10,000 to enhance its international operations[15]. - The company is actively involved in the investment of the Yinglian Fund, indicating a focus on strategic financial partnerships[21]. - The company is in the process of planning a new employee stock ownership plan for 2021[22].